Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131672 | 0.90 | RAB9A (0.49) | RAB9AMAP4K4JAK2FDPSCYP11B1 | |
| SCHEMBL3340079 | 0.86 | JAK2 (0.47) | JAK2FDPSCYP11B1CYP11B2PPIA | |
| SCHEMBL3338478 | 0.85 | RAB9A (0.56) | RAB9AMAP4K4MAP3K8MEN1KMT2A | |
| SCHEMBL3341282 | 0.85 | GHSR (0.54) | MAP4K4JAK2FDPSCYP11B1CYP11B2 | |
| SCHEMBL3339885 | 0.83 | RAB9A (0.54) | RAB9AMAP4K4FDPSMAP3K8RAF1 | |
| SCHEMBL3337222 | 0.83 | MAP4K4 (0.55) | RAB9AMAP4K4MAP3K8RAF1BRAF | |
| SCHEMBL3338466 | 0.82 | RAB9A (0.53) | RAB9AMAP4K4MAP3K8MEN1KMT2A | |
| SCHEMBL3336347 | 0.82 | RAB9A (0.53) | RAB9AMAP4K4FDPSMAP3K8MEN1 | |
| SCHEMBL3338589 | 0.81 | RAB9A (0.52) | RAB9AMAP4K4FDPSMAP3K8RAF1 | |
| SCHEMBL5129448 | 0.81 | JAK2 (0.43) | JAK2FDPSCYP11B1CYP11B2PPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | RAB9A 1092/4885MAP4K4 2433/4885JAK2 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.